U.S. employers project a median health care cost increase of 8% for 2025, according to International Foundation of Employee Benefit Plans survey results. This is an increase over similar surveys conducted in 2022 and 2023, which projected a 7% rise in costs. 

Causes of Cost Increases 

Employers shared their thoughts on the primary factors contributing to a rise in medical plan costs for 2025. The top four factors (listed by percent of employers that identified them as primary causes) are as follows: 

  • 20%—Catastrophic claims (up from 19% last year) 
  • 20%—Specialty/costly prescription drugs, (up from 16% last year) 
  • 18%—Medical provider costs (up from 14% last year) 
  • 16%—Utilization due to chronic health conditions (down from 22% last year). 

Respondents who selected specialty/costly prescription drugs as a primary reason for the cost increase indicated that the following types of drugs were predominantly responsible for the increase:  

  • 75%—Glucagon-like peptide-1 (GLP-1) drugs 
  • 19%—Cell and gene therapy 
  • 31%—Other specialty drugs. 

Employers are reporting that catastrophic claims and specialty drugs are amongst the significant drivers of the health care cost increases. When I spoke with Julie Stich, CEBS, Vice President of Content at the International Foundation she said that during 2024, employers have been implementing several strategies to manage costs, with an increased focus on utilization control and cost-sharing initiatives. 

Managing Costs 

When asked what types of initiatives would make the most impact on managing costs for 2025, employers indicated the following strategies for the coming plan year:  

  • 27%—Utilization control initiatives: e.g., prior authorization, case management, disease management, nurse advice lines (up from 22% last year) 
  • 21%—Cost-sharing initiatives: e.g., deductibles, coinsurance, copays, premium contributions (up from 16% last year) 
  • 15%—Plan design initiatives: e.g., dependent eligibility audits, high-deductible health plans, spousal surcharges/carve-outs, formulary changes (up from 12% last year)  
  • 9%—Purchasing/provider initiatives: e.g., telemedicine, price transparency tools, centers of excellence, health care navigators/advocates, coalitions, quality initiatives (down from 12% last year). 

Survey responses reflected in the survey report are for corporate employers and do not include public plans or collectively bargained plans. Visit www.ifebp.org/healthcarecosts2025 for more information and a copy of the full survey results. 

Cara McMullin

Communications Specialist

Favorite Foundation Product: Word on Benefits Blog

Benefits-related Topics That Interest Her Most: Equity and Inclusion, Workplace Wellness

Personal Insight: Cara loves live theatre, concerts, and festivals – lots of fantastic options in Wisconsin. In her spare time, you can also find her reading, streaming TV/movies and spending time with family and friends at local restaurants, outdoor concerts, and farmers markets.

Recommended Posts

GLP-1 Drug Coverage Continues to Rise in Canada 

Rebecca Plier
 

New Survey Data Reveals Prior Authorization or Other Utilization Management Strategies, Eligibility Requirements, Annual Maximum as Leading Cost Control Methods  A new survey report from the International Foundation of Employee Benefit Plans reveals updated Canadian employer coverage and cost-control mechanisms surrounding glucagon-like […]

GLP-1 Drugs Responsible for Over Ten Percent of Annual Claims 

Rebecca Plier
 

New Survey Data Reveals Rise of GLP-1 Drug Claims, With Utilization Management and Eligibility Requirements as Leading Cost-Control Mechanisms   A new survey report from the International Foundation of Employee Benefit Plans reveals updated U.S. employer coverage and claims representation surrounding glucagon-like peptide-1 […]

Mental Health Parity: Four Compliance Documents to Reference During Period of Nonenforcement for the 2024 Final Rule

Jenny Gartman, CEBS
 

The Departments of Labor (DOL), Health and Human Services (HHS), and the Treasury announced on May 15, 2025 that they will not enforce the portions of the 2024 final rule implementing the nonquantitative treatment limitation (NQTL) comparative analyses requirements under the Mental Health Parity […]